0001209191-23-006402.txt : 20230202
0001209191-23-006402.hdr.sgml : 20230202
20230202183747
ACCESSION NUMBER: 0001209191-23-006402
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230201
FILED AS OF DATE: 20230202
DATE AS OF CHANGE: 20230202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thye Dirk
CENTRAL INDEX KEY: 0001638945
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 23582868
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Quince Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662774
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 901024039
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-910-5717
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Cortexyme, Inc.
DATE OF NAME CHANGE: 20160104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-01
0
0001662774
Quince Therapeutics, Inc.
QNCX
0001638945
Thye Dirk
C/O CORTEXYME, INC.
601 GATEWAY BLVD, #1250
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
Chief Executive Officer
Employee Stock Option (right to buy)
0.94
2023-02-01
4
A
0
600000
0.00
A
2033-01-31
Common Stock
600000
600000
D
The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.
/s/ Ted Monohon, Attorney-in-Fact for Dirk Thye
2023-02-02